查看文章

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is the third leading cause of cancer-related death worldwide [1]. The reported annual incidence of HCC is rising in most countries, mostly due to the increasing burden of chronic hepatitis B and hepatitis C virus (HCV), along with the prevalence of other risk factors such as excessive alcohol consumption. Although new HCV therapies have proven effective, they are often expensive and not always universally accessible. Additionally, the increased incidence of nonalcoholic fatty liver disease secondary to obesity and diabetes contribute to new cases of HCC, especially in developed countries such as the USA [2–4]. The Barcelona Clinic Liver Cancer (BCLC) Classification is the gold-standard guideline for managing patients with HCC [5]. Early stages of HCC can be successfully managed with different treatment modalities, including hepatic …